UAE - GlaxoSmithKline plc and Innoviva Inc announced positive results in asthma control on the innovative Salford Lung Study (SLS). The results of the study show that more asthma patients initiated on treatment with Relvar Ellipta (FF/VI) achieved an improvement in their asthma control, compared to patients who continued to take their usual care medicines.
This pioneering open-label, randomised study was carried out in 4,233 patients treated by their own General Practitioner in everyday clinical practice. At 24 weeks, a significantly higher percentage (71%) of patients with asthma treated with Relvar Ellipta achieved better control of their asthma, compared with patients continuing usual care treatment (56%).
Asthma is a common chronic disease with an increasing prevalence across all regions of the world, particularly among children. Asthma has significant clinical, economic and humanistic burden in the Gulf Cooperation Council (GCC) countries, including reduced quality of life and healthcare costs. Previous study in the Gulf Cooperation Council (GCC) countries show that in UAE, the total direct medical cost of treating asthma patients in Abu Dhabi was estimated at AED 105 (USD 29) million and AED 88 (USD 24) million in Dubai[1]. In Kuwait, the costs for treating asthma patients is estimated at KD 58 (USD 207) million[2]. The total cost of in-patient treatments and emergency room visits for asthma in the Ministry of Health in KSA was estimated at SR 539 (USD 133) million and SR 376 (USD100) million respectively[3].
Andrew Miles, Vice President and General Manager of GSK in the GCC, commented: “Asthma continues to be a major burden to patients and healthcare systems in the region. Hence, we at GSK are committed to developing respiratory medicines that would address our patients’ needs and help elevate the healthcare industry as a whole. The results from SLS provide robust evidence that will enable the healthcare community to begin to understand how the choice of treatment can significantly influence patient outcomes.”
Lead Investigator, Ashley Woodcock, Professor of Respiratory Medicine and Clinical Director for Respiratory Medicine, University Hospital of South Manchester and University of Manchester said: “The Salford Lung Study is extremely important because it allows doctors to understand the effect of treatments in people living and managing their condition on a day-to-day basis. We are continuing to analyse the data from the study as we know there is so much more we will learn and we look forward to sharing our findings in the future.”
The need for data in a more representative population that reproduced everyday clinical practices is increasingly being recognised as an important complement to traditional efficacy trials in order to further inform the benefits and risks of medicines. The first multi-year drug trial under real world conditions allowed decision makers to better evaluate the effectiveness of medicines in a broader population sample.
-Ends-
[1] Bassam Hassan Saleh Hassan Mahboub, Sonia Santhakumar, Joan B. Soriano,1 and Ruby Pawankar. Asthma insights and reality in the United Arab Emirates. Ann Thorac Med. 2010 Oct-Dec; 5(4): 217–221. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954375/
[2]Khadadah, Mousa: The Cost of Asthma in Kuwait, Medical Principles and Practice 2013;22:87–91 http://bit.ly/2i8SvJg April 2012.
[3] Hasnain, Syed and AlQassim Alanoud, et al: Emerging Status of Asthma, Allergic Rhinitis and Eczema in the Middle East: Journal of Disease and Global Health March 2017 p.133 http://bit.ly/2u7TpZ9
© Press Release 2017
This pioneering open-label, randomised study was carried out in 4,233 patients treated by their own General Practitioner in everyday clinical practice. At 24 weeks, a significantly higher percentage (71%) of patients with asthma treated with Relvar Ellipta achieved better control of their asthma, compared with patients continuing usual care treatment (56%).
Asthma is a common chronic disease with an increasing prevalence across all regions of the world, particularly among children. Asthma has significant clinical, economic and humanistic burden in the Gulf Cooperation Council (GCC) countries, including reduced quality of life and healthcare costs. Previous study in the Gulf Cooperation Council (GCC) countries show that in UAE, the total direct medical cost of treating asthma patients in Abu Dhabi was estimated at AED 105 (USD 29) million and AED 88 (USD 24) million in Dubai[1]. In Kuwait, the costs for treating asthma patients is estimated at KD 58 (USD 207) million[2]. The total cost of in-patient treatments and emergency room visits for asthma in the Ministry of Health in KSA was estimated at SR 539 (USD 133) million and SR 376 (USD100) million respectively[3].
Andrew Miles, Vice President and General Manager of GSK in the GCC, commented: “Asthma continues to be a major burden to patients and healthcare systems in the region. Hence, we at GSK are committed to developing respiratory medicines that would address our patients’ needs and help elevate the healthcare industry as a whole. The results from SLS provide robust evidence that will enable the healthcare community to begin to understand how the choice of treatment can significantly influence patient outcomes.”
Lead Investigator, Ashley Woodcock, Professor of Respiratory Medicine and Clinical Director for Respiratory Medicine, University Hospital of South Manchester and University of Manchester said: “The Salford Lung Study is extremely important because it allows doctors to understand the effect of treatments in people living and managing their condition on a day-to-day basis. We are continuing to analyse the data from the study as we know there is so much more we will learn and we look forward to sharing our findings in the future.”
The need for data in a more representative population that reproduced everyday clinical practices is increasingly being recognised as an important complement to traditional efficacy trials in order to further inform the benefits and risks of medicines. The first multi-year drug trial under real world conditions allowed decision makers to better evaluate the effectiveness of medicines in a broader population sample.
-Ends-
[1] Bassam Hassan Saleh Hassan Mahboub, Sonia Santhakumar, Joan B. Soriano,1 and Ruby Pawankar. Asthma insights and reality in the United Arab Emirates. Ann Thorac Med. 2010 Oct-Dec; 5(4): 217–221. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954375/
[2]Khadadah, Mousa: The Cost of Asthma in Kuwait, Medical Principles and Practice 2013;22:87–91 http://bit.ly/2i8SvJg April 2012.
[3] Hasnain, Syed and AlQassim Alanoud, et al: Emerging Status of Asthma, Allergic Rhinitis and Eczema in the Middle East: Journal of Disease and Global Health March 2017 p.133 http://bit.ly/2u7TpZ9
© Press Release 2017
